QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use
Rhea-AI Summary
QuidelOrtho (NASDAQ: QDEL) has launched the QUICKVUE Influenza + SARS Test, a professional-use diagnostic tool that simultaneously detects and differentiates between influenza A, influenza B, and SARS-CoV-2 antigens from a single patient sample. The CLIA-waived, 510(k)-cleared test delivers results in as fast as 10 minutes.
The test is designed for use in physician office laboratories, urgent care centers, emergency departments, pharmacies, and decentralized hospital labs. Key features include triple detection capability, fast results, professional use designation, efficient workflow with easy-to-collect nasal swabs, and cost-effective visual combo testing. The product is available in the United States through QuidelOrtho's existing distribution channels but is not intended for in-home use.
Positive
- New test enables rapid differentiation between COVID-19 and flu in 10 minutes
- CLIA-waived and 510(k)-cleared status allows broad professional use across healthcare settings
- Expands QuidelOrtho's respiratory testing portfolio and reinforces market leadership
- Cost-effective solution for healthcare providers during seasonal respiratory surges
Negative
- None.
News Market Reaction – QDEL
In the Sep 22 session, QDEL declined 1.11%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The QUICKVUE Influenza + SARS Test is designed to deliver rapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigens from a single patient sample, providing results in as fast as 10 minutes. This capability can help clinicians distinguish between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes.
Key Features and Benefits:
- Triple Detection Capability: Differentiates influenza A/B and COVID-19 in one test.
- Fast Results: Clear results available in as fast as 10 minutes at the point of care.
- Professional Use: Designed for CLIA-waived and moderate/high-complexity lab settings.
- Efficient Workflow: Easy-to-collect nasal swab, streamlined processing and clear result window.
- Affordable Access: Cost-effective visual combo test.
"Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With the QUICKVUE Influenza + SARS Test, we're equipping healthcare providers with a reliable, affordable and efficient tool to differentiate between COVID-19 and influenza in minutes," said Tammi Ranalli, PhD, Senior Vice President, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho. "This innovation reflects QuidelOrtho's commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections."
The launch of the QUICKVUE Influenza + SARS Test expands QuidelOrtho's portfolio of respiratory solutions, including the
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
For more information, visit www.quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@QuidelOrtho.com
Media Contact:
D. Nikki Wheeler
Senior Director, Corporate Communications
media@QuidelOrtho.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-announces-availability-of-quickvue-influenza--sars-test-for-professional-use-302561981.html
SOURCE QuidelOrtho Corporation